LIM/13 - Laboratório de Genética e Cardiologia Molecular

URI Permanente desta comunidade

https://observatorio.fm.usp.br/handle/OPI/3646
O Laboratório de Genética e Cardiologia Molecular é ligado ao Departamento de Cardiopneumologia da Faculdade de Medicina da Universidade de São Paulo (FMUSP).

Linhas de pesquisa: identificação e caracterização de biomarcadores para utilização em algoritmos de apoio à decisão médica; desenvolvimento de estratégias para reparação de órgãos com baixa capacidade regenerativa; genética das doenças cardiovasculares; evolução das câmaras cardíacas; biologia do desenvolvimento do coração; cardiopatias congênitas; sinalização pelo ácido retinoico; desenvolvimento de vetores virais portadores de genes supressores de tumor e imunoestimuladores para terapia gênica do câncer.

Site oficial: http://limhc.fm.usp.br/portal/lim13-laboratorio-de-genetica-e-cardiologia-molecular/

Índice h

Scopus: 67
Exibir mais

Navegar

Coleções desta Comunidade

Agora exibindo 1 - 3 de 3

Submissões Recentes

article 1 Citação(ões) na Scopus
Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial
(2023) PEREIRA, M. D. P.; LIMA, E. G.; PITTA, F. G.; GOWDAK, L. H. W.; MIOTO, B. M.; CARVALHO, L. N. S.; DARRIEUX, F. C. D. C.; MEJIA, O. A. V.; JATENE, F. B.; SERRANO JR., C. V
Objectives: Postoperative atrial fibrillation is the most common clinical complication after coronary artery bypass graft surgery. It is associated with a high risk of both stroke and death and increases the length of hospital stay and costs. This study aimed to evaluate anticoagulants in postoperative atrial fibrillation. Methods: A single-center, randomized, prospective, and open-label study. The trial was conducted in Heart Institute at University of São Paulo, Brazil. Patients who developed postoperative atrial fibrillation were randomized to anticoagulation with rivaroxaban or warfarin plus enoxaparin bridging. The primary objective was the cost-effectiveness evaluated by quality-adjusted life years, using the SF-6D questionnaire. The secondary end point was the combination of death, stroke, myocardial infarction, thromboembolic events, infections, bleeding, readmissions, and surgical reinterventions. The safety end point was any bleeding using the International Society on Thrombosis and Haemostasis score. Follow-up period was 30 days after hospital discharge. Results: We analyzed 324 patients and 53 patients were randomized. The median cost-effectiveness was $1423.20 in the warfarin group versus $586.80 in the rivaroxaban group (P = .002). The median cost was lower in the rivaroxaban group, $450.20 versus $947.30 (P < .001). The secondary outcome was similar in both groups, 44.4% in warfarin group versus 38.5% in the rivaroxaban group (P = .65). Bleeding occured in 25.9% in the warfarin group versus 11.5% in the rivaroxaban group (P = .18). Conclusions: Rivaroxaban was more cost-effective when compared with warfarin associated with enoxaparin bridging in postoperative atrial fibrillation after isolated coronary artery bypass grafting.
article 0 Citação(ões) na Scopus
conferenceObject
Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry
(2023) MAURIZI, N.; DAY, S.; ASHLEY, E.; MICHELS, M.; PEREIRA, A. C.; HELMS, A.; SABERI, S.; JACOBY, D.; WARE, J.; COLAN, S.; SEMSARIAN, C.; INGLES, J.; HO, C.; OLIVOTTO, I.
conferenceObject
Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study
(2023) GOWDAK, L. Wolff; DOURADO, P.; PRECOMA, D.; DUSILEK, C.; SILVA, F.; YUGAR-TOLEDO, J.; PENA, F.; GOMES, D.; CESTARIO, E.; GUIMARAES JR., O.; HOFFMANN FILHO, C.; ALMEIDA, C.; BRITO, F.; MARTINS, G.; FERREIRA, V.
conferenceObject
Impact of Coronary Atherosclerotic Burden on the Long-Term Prognosis of Patients With Chronic Kidney Disease Undergoing Renal Replacement Therapy
(2023) GODINHO, Roger; CAMPOS, Carlos; ABIZAID, Alexandre; LIMA, Jose Jayme de; RIBEIRO, Henrique; LOPES, Neuza; MOTA, Gabriel; SANTOS, Luciano; GOWDAK, Luis; KALIL FILHO, Roberto; RIBEIRO, Expedito
conferenceObject
SITOSTEROLEMIA AND PREMATURE CORONARY ATHEROSCLEROSIS IN A YOUNG WOMAN: A CASE REPORT.
(2023) CORSO, Mariana P. Xerfan; MARTINHAGO, Gustavo; BORGES, Kartagena; BECERE, Matheus AndraDe lazzari; CHACRA, Ana Paula Marte; MIZUTA, Marjorie Hayashida; MINAME, Marcio Hiroshi; SANTOS, Raul; ROCHA, Viviane Zorzanelli
conferenceObject
Association of Lipoprotein Subfractions With Atherosclerosis in the Baseline Sample of ELSA-Brasil Cohort Study - A Cross-Sectional Analysis
(2023) TEBAR, William R.; MENEGHINI, Vandrize; GOULART, Alessandra C.; SANTOS, Itamar S.; SANTOS, Raul D.; BITTENCOURT, Marcio S.; GENEROSO, Giuliano; PEREIRA, Alexandre; BLAHA, Michael J.; JONES, Steven R.; TOTH, Peter P.; OTVOS, James D.; LOTUFO, Paulo A.; BENSENOR, Isabela M.
conferenceObject
GlycA, but Not C-reactive Protein is Associated With Baseline Carotid Artery Plaque in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
(2023) TEBAR, William R.; MENEGHINI, Vandrize; GOULART, Alessandra C.; SANTOS, Itamar S.; SANTOS, Raul D.; BITTENCOURT, Marcio S.; GENEROSO, Giuliano; PEREIRA, Alexandre C.; BLAHA, Michael J.; JONES, Steven R.; TOTH, Peter P.; OTVOS, James D.; LOTUFO, Paulo A.; BENSENOR, Isabela M.
article 6 Citação(ões) na Scopus
Update on Sitosterolemia and Atherosclerosis
(2023) ROCHA, Viviane Zorzanelli; TADA, Mauricio Teruo; CHACRA, Ana Paula Marte; MINAME, Marcio Hiroshi; MIZUTA, Marjorie H. H.
Purpose of ReviewThe purpose of this review was to summarize important and updated information on sitosterolemia. Sitosterolemia is an inherited lipid disorder consisting of high levels of plasma plant sterols. This sterol storage condition is caused by biallelic loss-of-function genetic variants in either ABCG5 or ABCG8, leading to increased intestinal absorption and decreased hepatic excretion of plant sterols. Clinically, patients with sitosterolemia usually exhibit xanthomatosis, high levels of plasma cholesterol, and premature atherosclerotic disease, but presentation can be highly heterogeneous. Therefore, recognition of this condition requires a high level of suspicion, with confirmation upon genetic diagnosis or through measurement of plasma phytosterols. Treatment of sitosterolemia with both a plant sterol-restricted diet and the intestinal cholesterol absorption inhibitor ezetimibe can reduce efficiently the levels of plasma plant sterols, consisting in the first-line therapy for this disease.Recent FindingsSince hypercholesterolemia is often present in individuals with sitosterolemia, it is important to search for genetic variants in ABCG5 and ABCG8 in patients with clinical criteria for familial hypercholesterolemia (FH), but no variants in FH implicated genes. Indeed, recent studies have suggested that genetic variants in ABCG5/ABCG8 can mimic FH, and even when in heterozygosis, they may potentially exacerbate the phenotype of patients with severe dyslipidemia.Sitosterolemia is a genetic lipid disorder characterized by increased circulating levels of plant sterols and clinically manifested by xanthomatosis, hematologic disorders, and early atherosclerosis. Awareness about this condition, a rare, but commonly underdiagnosed and yet treatable cause of premature atherosclerotic disease, is imperative.
article 0 Citação(ões) na Scopus
Effect of Low-Dose Progesterone on Glycemic Metabolism, Morphology and Function of Adipose Tissue and Pancreatic Islets in Diet-Induced Obese Female Mice
(2023) SANTOS, Matheus P.; CAUDURO, Leonardo F. R.; FERREIRA, Marilia Marcondes; MARTUCCI, Luiz Felipe; VECCHIATTO, Bruno; VILAS-BOAS, Eloisa Aparecida; AMERICO, Anna Laura V.; PEREIRA, Renata O.; ROGERO, Marcelo Macedo; FIORINO, Patricia; EVANGELISTA, Fabiana S.; AZEVEDO-MARTINS, Anna Karenina
Background: Obesity is a worldwide concern due to its global rapid expansion and remarkable impact on individual's health by predisposing to several other diseases. About twice as many women as men suffer from severe obesity and, in fact, there are stages in a woman's life when weight gain and adiposity can result in greater damage to health. For example, obesity triples the chance of a woman developing gestational diabetes. Many hormones promote the metabolic adaptations of pregnancy, including progesterone, whose role in female obesity is still not well known despite being involved in many physiological and pathological processes. Methods: Here we investigated whether progesterone treatment at low dose can worsen the glucose metabolism and the morpho functional aspects of adipose tissue and pancreas in obese females. Mice were assigned into four groups: normocaloric diet control (NO-CO), high-fat and -fructose diet control (HFF-CO), normocaloric diet plus progesterone (NO-PG) and high-fat and -fructose diet plus progesterone (HFF-PG) for 10 weeks. Infusion of progesterone (0.25 mg/kg/day) was done by osmotic minipump in the last 21 days of protocol. Results: Animals fed a hypercaloric diet exhibited obesity with increased body weight (p < 0.0001), adipocyte hypertrophy (p < 0.0001), hyperglycemia (p = 0.03), and glucose intolerance (p = 0.001). HFF-CO and HFF-PG groups showed lower adiponectin concentration (p < 0.0001) and glucose-stimulated insulin secretion (p = 0.03), without differences in islet size. Progesterone attenuated glucose intolerance in the HFFPG group (p = 0.03), however, did not change morphology or endocrine function of adipose tissue and pancreatic islets. Conclusions: Taken together, our results showed that low dose of progesterone does not worsen the effects of hypercaloric diet in glycemic metabolism, morphology and function of adipose tissue and pancreatic islets in female animals. These results may improve the understanding of the mechanisms underlying the pathogenesis of obesity in women and eventually open new avenues for therapeutic strategies and better comprehension of the interactions between progesterone effects and obesity.